ReNeuron Group plc announced the appointment of Catherine Isted, ACMA, as Chief Executive Officer, effective 1 September 2022. Ms. Isted joined the ReNeuron Board as Chief Financial Officer in October 2021. Following the departure of the former CEO in February this year, Ms. Isted has worked closely with the Executive Management team, led by Iain Ross, to refocus the business around the Group's differentiated exosomes delivery platform.
Ms. Isted is an experienced strategic finance professional and chartered management accountant with c.25 years' experience across the Healthcare industry. This includes 12 years at partner level in two leading Healthcare banking teams undertaking multiple Initial Public Offerings and follow-on fundraisings. Within the Healthcare industry, prior to joining ReNeuron, Ms. Isted has also held various in-house financial and strategic roles spanning Corporate Development, Investor Relations and Financial Planning and Analysis. Ms. Isted joined ReNeuron from Oxford Biomedica plc, a global leading cell and gene therapy company, where she was instrumental in raising in excess of £110 million and supporting potential board level strategic opportunities. She has also held senior research analyst and equity sales positions in the Healthcare teams at Morgan Stanley, ABN AMRO, Nomura and Peel Hunt. Ms. Isted holds a 1st Class chemistry degree along with experience as a bench scientist, before moving into finance and training as an accountant at Merck.